nyuuzyou/wikis huggingface dataset:
Pralsetinib (Gavreto)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, BLU-667 binds to and targets various RET mutants and RET-containing fusion product.
==Diseases for which it is used==
*RET-positive NSCLC
*Thyroid cancer, RET-positive
==History of changes in FDA indication - PARTIALLY WITHDRAWN==
*2020-09-04: Accelerated approval for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Based on ARROWRET-NSCLC)
*2020-12-01: Accelerated approval for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Based on ARROWRET-thyroid)
**2023-07-20: Accelerated approval for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy withdrawn.
*2020-12-01: Accelerated approval for adult and pediatric patients 12 years of age and older with RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Based on ARROWRET-thyroid)
*2023-08-09: Granted regular approval for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Based on ARROWRET-NSCLC)
==History of changes in EMA indication==
*2021-11-18: Initial conditional authorization
==History of changes in Health Canada indication==
*2021-06-30: Initial notice of compliance with conditions for the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)
==Also known as==
*Code name: BLU-667
*Brand name: Gavreto
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:RET inhibitors
Category:Non-small cell lung cancer medications
Category:Thyroid cancer medications
Category:EMA approved in 2021
Category:FDA approved in 2020
Category:Health Canada approved in 2021
Prasugrel (Effient)

==General information==
Class/mechanism: Irreversible thienopyridine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Also known as==
*Brand names: Effient, Efient, Glitax, Prasita, Prasudoc, PrasuSafe, Prax, Surfent, Targol
Category:Drugs
Category:Oral medications
Category:P2Y12 ADP inhibitors
Category:FDA approved in 2009
Prednimustine (Stereocyt)

The ester formed from two other drugs, prednisolone and chlorambucil
==Diseases for which it was used==
*Hodgkin lymphoma
*Ovarian cancer
==Also known as==
*Brand names: Mostarina, Sterocyt
Category:Drugs
Category:Oral medications
Category:Steroids
Category:Nitrogen mustards
Category:Classical Hodgkin lymphoma medications (historic)
Category:Ovarian cancer medications (historic)
Category:Stub
Presentations

This is a pilot project to make it easier for us to share, find, and learn from presentations prepared by our colleagues. Submitters may update or remove these presentations at any time--it is simple to upload new versions of files or remove files if you wish. The submitter of every presentation is responsible for making sure that they have the right/permission to post the content. If you believe that any content here violates your copyright, email contact@hemonc.org with the details and we will address it.
In the future, we will consider creating separate pages for every presentation and categorizing things by topic, author, type of presentation--Powerpoint, Twitter, Youtube, etc.
==Instructions==
To add something to this list, upload a file, choose a descriptive filename, and create a link to it below by doing one of the following:
===Via Visual Editor "Edit"===
#Go to the list below, and type in text to describe your presentation. 
#Highlight the text, click the "link," and type in the name of your uploaded file (can also upload using the Visual Editor via "insert" --> media). The format usually will be File:__name_of_your_uploaded_file__ 
=== Via "Edit Source" ===
#Edit the list below and put a link to the file by adding this: [[File:your_filename.ppt | the_text_you_want_to_be_shown_linking_to_your_file]]
#Click save page
==Powerpoints==
==Youtube==
Category:General reference pages
Category:Hematology reference pages
Category:Oncology reference pages
Procarbazine (Matulane)

==General information==
Class/mechanism: Hydrazine derivative, alkylator; exact mechanism not understood. May inhibit transmethylation of methionine methyl groups to tRNA, interfering with protein, RNA, and DNA synthesis. May also directly damage DNA.Procarbazine (Matulane) package insertProcarbazine (Matulane) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Diseases for which it is established==
*Classical Hodgkin lymphoma (FDA)
==Diseases for which it is used==
*Anaplastic glioma
*CNS lymphoma
*Glioblastoma
*Indolent lymphoma
*Low-grade glioma
*Mantle cell lymphoma
==Diseases for which it was used==
*Diffuse large B-cell lymphoma
*Non-small cell lung cancer
*Small cell lung cancer
==Patient drug information==
*Procarbazine (Matulane) patient drug information (Chemocare)Procarbazine (Matulane) patient drug information (Chemocare)
*Procarbazine (Matulane) patient drug information (UpToDate)Procarbazine (Matulane) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1969-07-22: Initial FDA approval
*Uncertain date: Approved for use in combination with other anticancer drugs for the treatment of stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. (Based on Young et al. 1973a, Kolygin 1976, possibly others)
==History of changes in EMA indication==
*1966-10-07: EURD
==Also known as==
*Code names: NCI-C01810, Ro 4-6467/1
*Generic names: ibenzmethyzin hydrochloride, ibenzmethyzine hydrochloride, procarbazine hydrochloride
*Brand names: Indicarb, Matulane, Natulan, Natulanar, P-Carbazine, P-Carzine
==References==
Category:Drugs
Category:Oral medications
Category:Triazenes
Category:Alkylating agents
Category:Human DNA synthesis inhibitors
Category:Anaplastic glioma medications
Category:Classical Hodgkin lymphoma medications
Category:CNS lymphoma medications
Category:Glioblastoma medications
Category:Indolent lymphoma medications
Category:Low-grade glioma medications
Category:Mantle cell lymphoma medications
Category:Diffuse large B-cell lymphoma medications (historic)
Category:Non-small cell lung cancer medications (historic)
Category:Small cell lung cancer medications (historic)
Category:FDA approved in 1969
Category:EMA approved in 1966
Category:WHO Essential Cancer Medicine
Prochlorperazine (Compazine)

==Mechanism of action==
Dopamine (D2) receptor antagonist 
==Also known as==
*Brand names: Acuvert, Compazine, Compro, Dvometil, Stemetil
Category:Drugs
Category:Intravenous medications
Category:Oral medications
Category:Rectal medications
Category:Emesis prevention
Category:Dopamine receptor antagonist
Category:Phenothiazines
Category:FDA approved in 1956
Promethazine (Phenergan)

==Mechanism of action==
First-generation antihistamine and dopamine receptor D2 antagonist. No known antineoplastic properties.
==Also known as==
*Brand name: Phenergan
Category:Drugs
Category:Oral medications
Category:Rectal medications
Category:Emesis prevention
Category:Dopamine receptor antagonist
Category:Phenothiazines
Category:FDA approved in 1951
Protamine sulfate (USP)

==General information==
Class/mechanism: Heparin antagonist; protamine sulfate is a weak anticoagulant that forms a stable salt with heparin, after which the anticoagulant effect of both drugs is negated.Protamine sulfate package insertProtamine sulfate package insert (locally hosted backup)University of Michigan Health System Anticoagulation Reversal
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Bleeding with anticoagulation
==Patient drug information==
*Protamine sulfate patient drug information (UpToDate)Protamine sulfate patient drug information (UpToDate)
==Also known as==
*Generic name: USP
==References==
Category:Drugs
Category:Intravenous medications
Category:Heparin antagonist
Category:Hemostasis medications
Category:FDA approved in 1969
Protein C, human (Ceprotin)

Human protein C
==History of changes in EMA indication==
*2001-07-16: Initial authorization as Ceprotin
*Uncertain date: CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans, coumarin-induced skin necrosis, and venous thrombotic events in patients with severe congenital protein C deficiency.
==Also known as==
*Brand name: Ceprotin
Category:Drugs
Category:Fractionated plasma products
Category:Intravenous medications
Category:Hematology medications
Category:Hemostasis medications
Category:Anticoagulation factors
Category:EMA approved in 2001
Category:Stub
Prothrombin Complex Concentrate, human

==General information==
Class/mechanism: Concentrate of vitamin K-dependent coagulation factors II (FII), VII (FVII), IX (FIX), X (FX), and protein C and protein S. Use of prothrombin complex concentrate can help control acute major bleeding that may result from acquired deficiency of vitamin K-dependent coagulation factors (supratherapeutic INR) in patients who are using vitamin K antagonists (VKA) such as Warfarin (Coumadin).Prothrombin Complex Concentrate, Human (Kcentra) package insert Prothrombin Complex Concentrate, Human (Kcentra) package insert (locally hosted backup)Kcentra manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Bleeding with anticoagulation
==Patient drug information==
*Prothrombin Complex Concentrate, Human (Kcentra) package insert
==History of changes in FDA indication==
*2013-04-29: Kcentra approved for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding.
*2023-07-25: Balfaxar approved for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. (Based on LEX-209)
==Also known as==
*Generic names: 4-factor prothrombin complex concentrate, factor IX complex, PCC, prothrombin complex concentrate human-lans
*Brand names: Balfaxar, Beriplex, Confidex, Kcentra, Octaplex, Profilnine
==References==
Category:Fractionated plasma products
Category:Intravenous medications
Category:Hematology medications
Category:Hemostasis medications
Category:Coagulation factors
Category:FDA approved in 2013
Pyrotinib (Irene)

==General information==
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells.
Route: PO
Extravasation: n/a
==Diseases for which it is used==
*HER2+ breast cancer
==History of changes in NMPA indication==
* 2018-08-22: Initial conditional authorization
==Also known as==
*Code name: SHR-1258
*Brand name: Irene
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:EGFR inhibitors
Category:ERBB2 inhibitors
Category:Breast cancer medications
Category:NMPA approved in 2018
Pyruvate kinase deficiency

Back to Top
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==International expert guidelines==
*2024: Al-Samkari et al. Diagnosis and management of pyruvate kinase deficiency: international expert guidelines EuroPMC
=All lines of therapy=
==Mitapivat monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Grace et al. 2019 (AG348-C-003) 	Not reported 	Phase 2 	 	
Glenthøj et al. 2022 (ACTIVATE-T)	2018-06-26 to 2020-02-04	Nonrandomized phase 3 (RT)	 	
Al-Samkari et al. 2022 (ACTIVATE)	2018-10-01 to 2020-10-09	Phase 3 (E-RT-esc) 	Placebo 	Better hemoglobin response
====Supportive therapy====
*Mitapivat (Pyrukynd) 5 mg PO twice per day
24-week course
===References===
#AG348-C-003: Grace RF, Rose C, Layton DM, Galactéros F, Barcellini W, Morton DH, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM, Sheth S, Kwiatkowski JL, Barbier AJ, Bodie S, Silver B, Hua L, Kung C, Hawkins P, Jouvin MH, Bowden C, Glader B. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. N Engl J Med. 2019 Sep 5;381(10):933-944. link to original article EuroPMC NCT02476916
#ACTIVATE: Al-Samkari H, Galactéros F, Glenthøj A, Rothman JA, Andres O, Grace RF, Morado-Arias M, Layton DM, Onodera K, Verhovsek M, Barcellini W, Chonat S, Judge MP, Zagadailov E, Xu R, Hawkins P, Beynon V, Gheuens S, van Beers EJ; ACTIVATE Investigators. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. N Engl J Med. 2022 Apr 14;386(15):1432-1442. link to original article dosing details in abstract have been reviewed by our editors EuroPMC NCT03548220
#ACTIVATE-T: Glenthøj A, van Beers EJ, Al-Samkari H, Viprakasit V, Kuo KHM, Galactéros F, Chonat S, Porter J, Zagadailov E, Xu R, Oluyadi A, Hawkins P, Gheuens S, Beynon V, Barcellini W; ACTIVATE-T investigators. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol. 2022 Oct;9(10):e724-e732. Epub 2022 Aug 18. link to original article EuroPMC NCT03559699
Category:Pyruvate kinase deficiency regimens
Category:Disease-specific pages
Category:Hemolytic process
Quisinostat (JNJ-26481585)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Quisinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Cutaneous T-cell lymphoma===
# Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016 Jul;175(1):80-8. Epub 2016 Jun 2. link to original article EuroPMC 
==Also known as==
*Code name: JNJ-26481585
Category:Drugs
Category:Oral medications
Category:HDAC inhibitors
Category:Cutaneous T-cell lymphoma medications (investigational)
Category:Investigational drugs
Quizartinib (Vanflyta)

==Mechanism of action==
FLT3 inhibitor
==Toxicity management==
*Link to REMS program
==Diseases for which it is established==
*FLT3+ AML
==History of changes in FDA indication==
*2023-07-20: Approved with standard cytarabine and anthracycline induction for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
*2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
*2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
==History of changes in EMA indication==
*2023-09-14: CHMP recommended marketing authorization at Vanflyta. Vanflyta would be indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.
==History of changes in PMDA indication==
*2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.
*2023-05-25: New indication and a new dosage for the treatment of newly diagnosed FLT3-ITD mutation-positive acute myeloid leukemia.
==Also known as==
*Code names: AC-220, ASP-2689
*Brand name: Vanflyta
Category:Drugs
Category:Oral medications
Category:FLT3 inhibitors
Category:Acute myeloid leukemia medications
Category:PMDA approved in 2019
Category:FDA approved in 2023
Category:REMS program
Racotumomab (Vaxira)

This drug is currently approved in Argentina and Cuba.
==Mechanism of action==
From Wikipedia: Racotumomab is an anti-idiotypic mouse monoclonal antibody that mimics NGc gangliosides, thus triggering an immune response against the tumor antigen NGcGM3. Therefore, rather than being a passive antibody therapy, Racotumomab acts as a therapeutic vaccine.
==Diseases for which it is used==
*Non-small cell lung cancer
==Also known as==
*Brand name: Vaxira
Category:Drugs
Category:Intravenous medications
Category:Anti-NGcGM3 antibodies
Category:Non-small cell lung cancer medications
Category:Stub
Radiotherapy toxicity management

Back to Top
The purpose of this page is to address the management of toxicity from radiation therapy.
To be created!
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==ASCO==
*2008: Hensley et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants EuroPMC
**2002: Schuchter et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology EuroPMC
**1999: Hensley et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants EuroPMC
Category:Radiation
Category:Supportive oncology
Radium-223 (Xofigo)

==General information==
Class/mechanism: Radioactive pharmaceutical agent (radium-223) that mimics some biologic behaviors of calcium and is incorporated into areas with increased bone turnover, such as bone metastases, by forming complexes with hydroxyapatite. Radium-223 emits alpha radiation at the site of bone metastases, which causes double-strand DNA breaks in nearby cells. The limited penetration of alpha radiation (less than 100 micrometers/uM, less than 10 cell diameters) is believed to limit the risk of adverse side effects. Radium-223's half-life is 11.4 days. Its specific activity is 1.9 MBq (51.4 microcurie)/ng; molecular weight of 223RaCl2: 293.9 g/mol.Radium Ra 223 (Xofigo) package insert Radium Ra 223 (Xofigo)‎ package insert (locally hosted backup)Xofigo manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Radium-223 (Xofigo) patient drug information (Chemocare)Radium-223 (Xofigo) patient drug information (Chemocare)
*Brief patient counseling information can be found in the Radium-223 (Xofigo) package insert
==History of changes in FDA indication==
*2013-05-15: FDA approved for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. (Based on ALSYMPCA)
==History of changes in EMA indication==
*2013-11-13: Initial marketing authorization as Xofigo. Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. (Based on ALSYMPCA)
==History of changes in Health Canada indication==
*2013-12-12: Initial notice of compliance (details unavailable)
==History of changes in PMDA indication==
*2016-03-28: Initial approval for the treatment of castration-resistant prostate cancer with bone metastases.
==Also known as==
*Generic names: Ra-223, Radium Ra 223 dichloride, Radium-223 chloride
*Brand names: Alpharadin, Xofigo
==References==
Category:Drugs
Category:Intravenous medications
Category:Radiotherapy medications
Category:Alpha emitters
Category:Prostate cancer medications
Category:EMA approved in 2013
Category:FDA approved in 2013
Category:Health Canada approved in 2013
Category:PMDA approved in 2016